ReviewJournal of the American College of Cardiology2018
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
Review in Journal of the American College of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 11 syntheses or guidelines pooled it, 479 citations in OpenAlex.
- Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Pooled it
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Causal association between lipoproteins and risk of coronary artery disease-a systematic review and meta-analysis of Mendelian randomization studies.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- Association of lipoprotein(a) and LPA gene with calcific aortic valve disease.European journal of medical research · 2025Pooled it
- The role of elevated lipoprotein(a) in aortic valve disease: a systematic review.Frontiers in cardiovascular medicine · 2025Pooled it
- Pooled it
- Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis.Cardiovascular research · 2023Pooled it
- Pooled it
- Integrated identification of key immune related genes and patterns of immune infiltration in calcified aortic valvular disease: A network based meta-analysis.Frontiers in genetics · 2022Pooled it
- Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events.Journal of the American Heart Association · 2020Pooled it
- Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.European journal of preventive cardiology · 2020Pooled it
- Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients.Journal of the American Heart Association · 2026Trial
- Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Trial
- On-treatment platelet reactivity through the thromboxane AJournal of thrombosis and thrombolysis · 2023Trial
- Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.Journal of the American College of Cardiology · 2022Trial
- Trial
- Association between serum lipoprotein(a) levels and aortic vulnerable plaques assessed by non-obstructive general angioscopy.Atherosclerosis plus · 2026Article
- RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms.Current atherosclerosis reports · 2026Review
- A Novel Triglyceride- and Cholesterol-Enriched Lipoprotein(a) Phenotype in Moderate Hypertriglyceridemia: Reversal by ApoC-III Inhibition.JACC. Basic to translational science · 2026Article
- Observational study: Temporal dynamics of lipoprotein(a) after out-of-hospital cardiac arrest: The Biobank Working Group.Resuscitation plus · 2026Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 3 countries.
Funding
Abstract
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.